Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HCP1904-1 in Essential Hypertension
NCT04820907Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of losartan in essential hypertension, sponsored by Hanmi Pharmaceutical. Started Oct 2020; status: completed.
02
Drugs
losartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT04820907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820907.